Biomedical Catalyst – Staphylococcus aureus Vaccine

金黄色葡萄球菌是一种细菌，它定植在30%的人的鼻衬和皮肤上。违反自然屏障的事故、手术或装置植入允许入侵，这可能导致危及生命的感染，如肺炎和血液传播感染，特别是通过抗生素耐药形式(MRSA)。尽管多次尝试金黄色葡萄球菌，但目前还没有疫苗可用。尽管临床前动物模型数据前景看好，但所有疫苗临床试验都失败了。由Absynth Biologics Limited和谢菲尔德大学领导的这个项目的合作伙伴和分包商正在汇集解决这一问题的能力，即：更有效地刺激人类免疫系统的新疫苗靶标和技术。这一点，再加上对感染发展(生理和免疫学)的更多了解，将被创新地用于为临床开发选择最佳候选疫苗。

S. aureus is a bacterium that colonises the nasal lining and skin of >30% of people. Accidents, surgery or device implantation that breach natural barriers, allow invasion, which may result in life-threatening infections such as pneumonia and blood-borne infections particularly by the antibiotic resistant form (MRSA). Despite several attempts S. aureus no vaccine is yet available. All vaccine clinical trials have failed despite promising pre-clinical animal model data. The partners and subcontractors in this project led by Absynth Biologics Limited and the University of Sheffield are bringing together capabilities to address this problem namely: novel vaccine targets and technologies to more effectively stimulate the human immune system. This coupled with a greater understanding of the development of infection (physiological and immunological) will be used innovatively to select the best candidate vaccine for clinical development.